New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2012
12:12 EDTSNX, BMY, CVX, TYC, AMLN, RDS.A, ALIM, PNR, BNNY, XOMOn The Fly: Mid-Day Wrap
Stocks on Wall Street are lower at mid-day, after a report on durable goods orders in February fell short of expectations. After a meandering start to the session the averages have found their direction and it is lower. Each of the major equity indices is firmly in negative territory and at session lows. The market began the session mixed and seemed unaffected by the generally in-line durable goods orders report. The market also ignored the weekly DOE energy inventory reports until the averages broke out of their tight range and moved to the downside, gaining negative momentum as the day progresses... ECONOMIC EVENTS: In the U.S., durable goods orders for February rose 2.2%, versus expectations for a 3.0% increase. The core reading, which excludes transportation items, increased 1.6%, versus the expected increase of 1.7%... MARKET NEWS: Exxon Mobil (XOM), Shell (RDS.A), BP (BP), and Chevron (CVX) all declined as oil prices dropped following statements from France's energy minister about a possible joint oil reserve release coordinated between France, the U.S. and the U.K... Organic pasta maker Annie's (BNNY) soared after the company's initial public offering, which priced above its expected range at $19. The stock is up almost 72% to $32.63 near noon... MAJOR MOVERS: Among the notable gainers were Amylin (AMLN), after Bloomberg reported that the company rejected a $22 per share takeover offer from Bristol-Myers (BMY) earlier this year, and Pentair (PNR), after the company agreed to merge with Tyco's (TYC) Flow Control business to create a combined company that sees pro forma 2012 revenues of $7.7B. Noteworthy losers included SYNNEX (SNX), following a downgrade at Citigroup on the company's disappointing guidance for Q2, and Alimera (ALIM), after the company said last night that based on recent discussions with European regulatory authorities it thinks it will take longer than originally anticipated to obtain marketing authorizations for it ILUVIEN drug... INDICES: Near noon, the Dow was down 83.97, or 0.64%, to 13,113.76; the Nasdaq was down 24.20, or 0.78%, to 3,096.15; and the S&P 500 was down 11.26, or 0.80%, to 1,401.26.
News For A;CVX;BNNY;AMLN;BMY;PNR;TYC;SNX;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
January 29, 2016
06:05 EDTTYCTyco sees Q2 EPS 44c-46c, consensus 46c
06:04 EDTTYCTyco reports Q1 EPS ex-items 42c, consensus 41c
Subscribe for More Information
January 28, 2016
14:29 EDTCVXNotable companies reporting before tomorrow's open
Subscribe for More Information
13:20 EDTCVXChevron volatility elevated into Q4 and outlook
Subscribe for More Information
12:42 EDTBMYBristol-Myers says EU approves Daklinza for treatment of chronic hepatitis C
Bristol-Myers Squibb announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C in three new patient populations. The expanded label allows for the use of Daklinza in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union. Daklinza is already approved by the European Commission for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults, and the Daklinza + sofosbuvir regimen is the only approved 12-week, all-oral treatment for genotype 3 HCV patients without cirrhosis. The new indications are based on data from the ALLY-1 clinical trial and ALLY-2 clinical trial. The recommended treatment regimens and durations are as follows:
11:14 EDTTYCJohnson Controls continues to expect at least $650M in synergies from merger
Oost merger, the company expects $4.5B EBITDA, $500M operating synergies and $150M tax synergies.
11:12 EDTTYCJohnson Controls sees no hiccups, improved momentum for Tyco transaction
Subscribe for More Information
10:55 EDTCVXOPEC delegates say no plan for meeting Russia about production, Bloomberg says
Subscribe for More Information
09:27 EDTBMYBristol-Myers reports Q4 US revenue $2.3B
Subscribe for More Information
09:27 EDTBMYBristol-Myers sees FY16 non-GAAP EPS $2.30-$2.40, consensus $2.29
Sees FY16 revenue up in mid-single digit range, consensus $17.4B. Sees FY16 gross margin as percentage of revenue ot be approximately 75%-76%. Sees FY16 marketing, sales and administrative expenses decreasing in mid-single digit range. Sees FY16 R&D expenses increasing in high-single digit range. Sees FY16 effective tax rate between 21%-22%.
09:25 EDTBMYBristol-Myers reports Q4 non-GAAP EPS 38c, consensus 28c
Reports Q4 revenue $4.29B, consensus $4.15B.
07:11 EDTBMYBristol-Myers: DMC concluded that CheckMate Phase 3 study met primary endpoint
07:00 EDTBMYBristol-Myers says CheckMate-141 Opdivo Phase 3 trial stopped early
Bristol-Myers Squibb announced that a randomized Phase 3 study evaluating Opdivo versus investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company looks forward to sharing these data with health authorities soon. "With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options," said Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb. "We look forward to continuing to advance the Opdivo clinical development program in hard-to-treat cancers, such as head and neck cancer." CheckMate -141 investigators have been informed of the decision to stop the trial early and Bristol-Myers Squibb is working to ensure that eligible patients be provided the opportunity to continue or start treatment with Opdivo as part of the company's commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -141 data, and work with investigators on the future presentation and publication of the results.
January 27, 2016
14:34 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
14:17 EDTBMYBristol-Myers technical comments before earnings news
Subscribe for More Information
13:55 EDTBMYBristol-Myers volatility elevated into Q4 and outlook
Bristol-Myers Black & Decker January weekly call option implied volatility is at 49, February is at 30; compared to its 52-week range of 18 to 43, suggesting large near term price movement into the expected release of Q4 results on January 28.
January 26, 2016
19:02 EDTCVXChevron announces first gas from Chuandongbei Project in Southwest China
Subscribe for More Information
07:53 EDTTYCJohnson Controls weakness a buying opportunity, says UBS
Subscribe for More Information
07:09 EDTTYCJohnson Controls acquisition of Tyco makes sense, says RBC Capital
Subscribe for More Information
06:24 EDTTYCJohnson Controls-Tyco merger should let Johnson reduce tax rate, WSJ says
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use